12 Health Care Stocks Moving In Thursday's Intraday Session

Benzinga · 03/12 17:05
Gainers
- Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock rose 34.2% to $0.14 during Thursday's regular session.
- Codexis (NASDAQ:CDXS) shares moved upwards by 33.85% to $1.7. The company's market cap stands at $114.7 million. As per the news, the Q4 earnings report came out yesterday.
- Agape ATP (NASDAQ:ATPC) stock rose 23.5% to $5.15. The company's market cap stands at $4.1 million.
- Quantum BioPharma (NASDAQ:QNTM) stock moved upwards by 22.38% to $2.57. The market value of their outstanding shares is at $8.0 million.
- ALPS Group (NASDAQ:ALPS) shares moved upwards by 20.61% to $1.17. The market value of their outstanding shares is at $161.4 million.
- Scienture Holdings (NASDAQ:SCNX) stock rose 16.35% to $0.54. The market value of their outstanding shares is at $18.8 million.
Losers
- Incannex Healthcare (NASDAQ:IXHL) shares declined by 38.0% to $3.7 during Thursday's regular session. The market value of their outstanding shares is at $71.3 million.
- Acurx Pharmaceuticals (NASDAQ:ACXP) stock decreased by 24.38% to $4.56. The company's market cap stands at $15.3 million.
- Rapid Micro Biosystems (NASDAQ:RPID) shares decreased by 21.58% to $3.44. The company's market cap stands at $194.1 million. The company's, Q4 earnings came out today.
- Polaryx Therapeutics (NASDAQ:PLYX) shares decreased by 20.49% to $4.58. The company's market cap stands at $272.6 million.
- Kala Bio (NASDAQ:KALA) stock fell 17.76% to $0.3. The market value of their outstanding shares is at $332.5 million.
- 60 Degrees (NASDAQ:SXTP) shares fell 17.71% to $2.65. The company's market cap stands at $4.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.